Examination of metformin hydrochloride in a continuous dissolution/HDM system

International Journal of Pharmaceutics

Volumn 351, Issue 1-2, 2008, Pages 127-132

  Fliszar, Kyle A ^a   Foster, Natalie ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b LEHIGH UNIVERSITY   (United States)

Author keywords

Absorption; Dissolution; Metformin hydrochloride

Indexed keywords

HEXADECANE; METFORMIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG ABSORPTION; DRUG FORMULATION; DRUG SOLUBILITY; MEMBRANE; PRIORITY JOURNAL;

ADULT; ALKANES; AREA UNDER CURVE; DELAYED-ACTION PREPARATIONS; FEMALE; FORECASTING; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEMBRANES, ARTIFICIAL; METFORMIN; MIDDLE AGED; PERMEABILITY; SOLUBILITY;

EID: 38749118289     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.09.023     Document Type: Article

References (25)

1. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochim. Biophys. Acta 175 (1991) 880-885
3. Blume H., and Schug B. The biopharmaceutic classification system (BCS): Class III drugs-better candidates for BA/BE waiver?. Eur. J. Pharm. Sci. 9 (1999) 117-121
4. Bretnall A., and Clarke G. Metformin hydrochloride. In: Brittain H.G. (Ed). Analytical Profiles of Drug Substances and Excipients 25 (1998), Academic Press, San Diego (CA) 243-293
5. Cheng C., Yu L., Lee H., Yang C., Lue C., and Chou C. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur. J. Pharm. Sci. 22 (2004) 297-304
6. Dressman J.B., Amidon G.L., and Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. 74 (1985) 588-589
7. FDA Guidance for Industry, 2000. Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based ona biopharmaceutics classification system. CDER/FDA.
8. Gillespie W.R. Convolution based approaches for in vivo in vitro correlation modeling. Adv. Exp. Med. Biol. 423 (1997) 53-65
9. Ginski M.J., and Polli J.E. Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system. Int. J. Pharm. 177 (1999) 117-125
10. Guidance for industry immediate release solid oral dosage forms scale-up and post approval changes: Chemistry, manufacturing and controls, 1997. In vitro dissolution testing and in vivo bioequivalence documentation. Center for drug evaluation and research (CDER), CMC 5.
11. Human medicines evaluation unit, 1999. Note for guidance on quality of modified release products: A. oral dosage forms; B. Transdermal dosage forms; Section 1 (Quality). The European agency for the Evaluation of Medicinal Products (EMEA), CPMP/QWP/604/96.
12. Kansay M., Senner F., and Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41 (1998) 1007-1010
13. Kobayashi M., Sada N., Sugawara M., Iseki K., and Miyazaki K. Development of a new system for prediction of drug absorption that takes into account drug dissolution and pH change in the gastro-intestinal tract. Int. J. Pharm. 221 (2001) 87-94
14. Li S., He H., Parthiban L., Yin H., and Serajuddin A. IV-IVC considerations in the development of immediate-release oral dosage form. J. Pharm. Sci. 94 (2005) 1396-1414
15. Lindenberg M., Kopp S., and Dressman J. Classification of orally administered drugs on the World Health Organization model list of essential medicines. Eur. J. Pharm. Biopharm. 58 (2004) 265-278
16. Matsson P., Bergstrom C., Nagahara N., Tavelin S., Norinder U., and Artursson P. Exploring the role of different drug transport routes in permeability screening. J. Med. Chem. 48 (2005) 604-613
17. Pagliara A., Reist M., Geinoz S., Carrupt P.A., and Testa B. Evaluation and prediction of drug permeation. J. Pharm. Pharmacol. 51 (1999) 1339-1357
18. Tavelin S., Taipalensuu J., Soderberg L., Morrison R., Chong S., and Artursson P. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm. Res. 20 (2003) 397-405
19. Timmins P., Donahue S., Meeker J., and Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin. Pharm. 44 (2005) 721-729
20. Uchiyama M. Prospect of drug product quality-regulatory considerations. Proc. Int. Symp. Control. Release Bioact. Mater. 23 (1996) 63
21. Upoor V. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J. Control. Release 72 (2001) 127-132
22. Usansky H.H., and Sinko P.J. Estimating Human Drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for ka and Fa. J. Pharmacol. Exp. Ther. 314 (2005) 391-399
23. Veng-Pedersen P., Gobburu J., Meyer M., and Straughn A. Carbamazepine level-A in vivo in vitro correlation (IVIVC): a scaled convolution based predictive approach. Biophar. Drug Dispos. 21 (2000) 1-6
24. Wohnsland F., and Faller B. High-throughput permeability pH profile and high-throughput alkane/water logP with artificial membranes. J. Med. Chem. 44 (2001) 923-930
25. Yu L.X., and Amidon G.L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 186 (1999) 119-125